| Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage … A Gallamini, M Hutchings, L Rigacci, L Specht, F Merli, M Hansen, C Patti, ... Journal of clinical oncology 25 (24), 3746-3752, 2007 | 981 | 2007 |
| ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned S Viviani, PL Zinzani, A Rambaldi, E Brusamolino, A Levis, V Bonfante, ... New England Journal of Medicine 365 (3), 203-212, 2011 | 455 | 2011 |
| Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy A Santoro, G Bonadonna, P Valagussa, R Zucali, S Viviani, F Villani, ... J Clin Oncol 5 (1), 27-37, 1987 | 452 | 1987 |
| ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results G Bonadonna, V Bonfante, S Viviani, A Di Russo, F Villani, P Valagussa Journal of Clinical Oncology 22 (14), 2835-2841, 2004 | 422 | 2004 |
| Gemcitabine in the treatment of refractory Hodgkin’s disease: results of a multicenter phase II study A Santoro, H Bredenfeld, L Devizzi, H Tesch, V Bonfante, S Viviani, ... Journal of Clinical Oncology 18 (13), 2615-2619, 2000 | 288 | 2000 |
| The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ... Haematologica 99 (6), 1107, 2014 | 271 | 2014 |
| Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. V Bonfante, A Santoro, S Viviani, L Devizzi, M Balzarotti, F Soncini, ... Journal of Clinical Oncology 15 (2), 528-534, 1997 | 255 | 1997 |
| Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. S Viviani, G Bonadonna, A Santoro, V Bonfante, M Zanini, L Devizzi, ... Journal of Clinical Oncology 14 (5), 1421-1430, 1996 | 225 | 1996 |
| Testicular dysfunction in Hodgkin's disease before and after treatment S Viviani, G Ragni, A Santoro, L Perotti, E Caccamo, E Negretti, ... European Journal of Cancer and Clinical Oncology 27 (11), 1389-1392, 1991 | 193 | 1991 |
| Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study … B Sarina, L Castagna, L Farina, F Patriarca, F Benedetti, AM Carella, ... Blood, The Journal of the American Society of Hematology 115 (18), 3671-3677, 2010 | 190 | 2010 |
| Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse CH Moskowitz, J Walewski, A Nademanee, T Masszi, E Agura, ... Blood, The Journal of the American Society of Hematology 132 (25), 2639-2642, 2018 | 183 | 2018 |
| Early chemotherapy intensification with BEACOPP in advanced‐stage Hodgkin lymphoma patients with a interim‐PET positive after two ABVD courses A Gallamini, C Patti, S Viviani, A Rossi, F Fiore, F Di Raimondo, ... British journal of haematology 152 (5), 551-560, 2011 | 170 | 2011 |
| Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma E Tiacci, E Ladewig, G Schiavoni, A Penson, E Fortini, V Pettirossi, ... Blood, The Journal of the American Society of Hematology 131 (22), 2454-2465, 2018 | 161 | 2018 |
| Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed … A Gallamini, C Tarella, S Viviani, A Rossi, C Patti, A Mulé, M Picardi, ... Journal of Clinical Oncology 36 (5), 454-462, 2018 | 161 | 2018 |
| The biological significance of soluble interleukin-2 receptors in solid tumors P Lissoni, S Barni, F Rovelli, S Viviani, GJM Maestroni, A Conti, G Tancini European Journal of Cancer and Clinical Oncology 26 (1), 33-36, 1990 | 155 | 1990 |
| Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and … P Lissoni, F Malugani, A Bonfanti, R Bucovec, S Secondino, F Brivio, ... Journal of biological regulators and homeostatic agents 15 (2), 140-144, 2001 | 145 | 2001 |
| CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin’s disease: associations with presenting features and clinical outcome GZ Rassidakis, LJ Medeiros, S Viviani, V Bonfante, GP Nadali, ... Journal of Clinical Oncology 20 (5), 1278-1287, 2002 | 140 | 2002 |
| BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens GZ Rassidakis, LJ Medeiros, TP Vassilakopoulos, S Viviani, V Bonfante, ... Blood, The Journal of the American Society of Hematology 100 (12), 3935-3941, 2002 | 134 | 2002 |
| Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome G Nadali, L Tavecchia, E Zanolin, V Bonfante, S Viviani, E Camerini, ... Blood, The Journal of the American Society of Hematology 91 (8), 3011-3016, 1998 | 120 | 1998 |
| Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials PL Zinzani, S Viviani, A Anastasia, U Vitolo, S Luminari, F Zaja, ... haematologica 98 (8), 1232, 2013 | 95 | 2013 |
